McKesson Corporation (MCK) EBITDA Margin: 1.78%
Is McKesson Corporation’s EBITDA margin high or low?
McKesson Corporation's EBITDA margin of 1.78% is 65% above its 5-year average of 1.08%, near the high end of its 5-year range (-1.51%–2.07%).
As of Saturday, June 20, 2026. 9.88% above its 12-month average of 1.62%.
MCK EBITDA Margin Chart
MCK Average EBITDA Margin Chart
MCK Current vs Average EBITDA Margin Chart
MCK EBITDA Margin Metrics
EBITDA MARGIN
1.78%
EBITDA MARGIN AVG TTM
1.62%
EBITDA MARGIN AVG 3Y
1.71%
EBITDA MARGIN AVG 5Y
1.08%
EBITDA MARGIN AVG 10Y
1.41%
EBITDA MARGIN AVG 15Y
1.71%
EBITDA MARGIN AVG 20Y
1.75%
CURRENT VS TTM AVG
+9.88%
CURRENT VS 3Y AVG
+4.40%
CURRENT VS 5Y AVG
+64.56%
CURRENT VS 10Y AVG
+26.49%
CURRENT VS 15Y AVG
+4.14%
CURRENT VS 20Y AVG
+1.59%
MCK Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| McKesson Corporation (MCK) | $87.88B | 1.78% | 1.62% | 1.71% | 1.08% |
| Elevance Health Inc. (ELV)vs › | $84.37B | 4.85% | 5.39% | 5.84% | 6.22% |
| HCA Healthcare, Inc. (HCA)vs › | $83.23B | 20.64% | 20.16% | 20.49% | 20.85% |
| Medtronic plc (MDT)vs › | $101.86B | 26.97% | 27.23% | 26.91% | 26.72% |
| Cigna Corporation (CI)vs › | $73.88B | 4.22% | 4.42% | 5.04% | 5.39% |
| Boston Scientific Corporation (BSX)vs › | $67.32B | 25.42% | 24.47% | 23.70% | 21.87% |
| Bristol-Myers Squibb Company (BMY)vs › | $110.27B | 30.18% | 18.37% | 30.35% | 29.39% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $62.84B | 40.57% | 39.01% | 39.25% | 44.24% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $114.63B | 40.28% | 22.34% | 35.25% | 38.74% |
| Stryker Corporation (SYK)vs › | $118.00B | 25.14% | 23.50% | 23.36% | 22.67% |
Margin Comparison
Gross Margin
3.6%
EBITDA Margin
1.8%
Operating Margin
1.6%
Net Margin
1.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
McKesson Corporation EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
McKesson Corporation EBITDA Margin FAQ
- What is the EBITDA margin for McKesson Corporation (MCK)?
- The EBITDA margin for MCK stock is 1.78%.
- Is McKesson Corporation's EBITDA margin high or low?
- McKesson Corporation's EBITDA margin of 1.78% is 65% above its 5-year average of 1.08%, near the high end of its 5-year range (-1.51%–2.07%).
- What is the TTM average EBITDA margin for McKesson Corporation (MCK)?
- The TTM average EBITDA margin for MCK stock is 1.62%.
- What is the 3Y average EBITDA margin for McKesson Corporation (MCK)?
- The 3Y average EBITDA margin for MCK stock is 1.71%.
- What is the 5Y average EBITDA margin for McKesson Corporation (MCK)?
- The 5Y average EBITDA margin for MCK stock is 1.08%.
- What is the 10Y average EBITDA margin for McKesson Corporation (MCK)?
- The 10Y average EBITDA margin for MCK stock is 1.41%.
- What is the 15Y average EBITDA margin for McKesson Corporation (MCK)?
- The 15Y average EBITDA margin for MCK stock is 1.71%.
- What is the 20Y average EBITDA margin for McKesson Corporation (MCK)?
- The 20Y average EBITDA margin for MCK stock is 1.75%.
McKesson Corporation EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | 1.78% |
| 2025-03-31 | 1.46% |
| 2024-03-31 | 1.51% |
| 2023-03-31 | 2.07% |
| 2022-03-31 | 1.18% |
| 2021-03-31 | -1.51% |
| 2020-03-31 | 1.00% |
| 2019-03-31 | 0.85% |
| 2018-03-31 | 0.71% |
| 2017-03-31 | 4.08% |
| 2016-03-31 | 2.35% |
| 2015-03-31 | 2.26% |
| 2014-03-31 | 2.22% |
| 2013-03-31 | 2.24% |
| 2012-03-31 | 2.22% |
| 2011-03-31 | 2.08% |
| 2010-03-31 | 2.32% |
| 2009-03-31 | 1.55% |
| 2008-03-31 | 1.94% |
| 2007-03-31 | 1.82% |
| 2006-03-31 | 1.73% |
| 2005-03-31 | 0.15% |
| 2004-03-31 | 1.74% |
| 2003-03-31 | 1.63% |
| 2002-03-31 | 1.81% |
| 2001-03-31 | 1.07% |
| 2000-03-31 | 0.90% |
| 1999-03-31 | 1.75% |
| 1998-03-31 | 2.15% |
| 1997-03-31 | 1.28% |
Related Metrics
About McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler